S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
66,000% upside on tiny biotech? (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
66,000% upside on tiny biotech? (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
66,000% upside on tiny biotech? (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
66,000% upside on tiny biotech? (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
66,000% upside on tiny biotech? (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Forecast, Price & News

$3.22
-0.06 (-1.83%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$3.17
$3.45
50-Day Range
$3.22
$5.97
52-Week Range
$2.77
$6.45
Volume
43,500 shs
Average Volume
78,661 shs
Market Capitalization
$99.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Anixa Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.1% Upside
$10.50 Price Target
Short Interest
Bearish
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Anixa Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.43) to $2.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

727th out of 1,010 stocks

Pharmaceutical Preparations Industry

368th out of 494 stocks


ANIX stock logo

About Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Stock News Headlines

The Latest Analyst Ratings for Anixa Biosciences
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Expert Ratings for Anixa Biosciences
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Chardan Capital Sticks to Its Buy Rating for Anixa Biosciences (ANIX)
Chardan Capital Sticks to Its Buy Rating for Immunome (IMNM)
See More Headlines
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Company Calendar

Last Earnings
3/16/2023
Today
5/29/2023
Next Earnings (Estimated)
6/09/2023
Fiscal Year End
10/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIX
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+226.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$510,000.00
Book Value
$0.92 per share

Miscellaneous

Free Float
24,616,000
Market Cap
$99.56 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Amit D. KumarAmit D. Kumar
    Executive Chairman & Chief Executive Officer
  • Michael J. Catelani
    President, COO, CFO & Secretary
  • Pamela D. Garzone
    Chief Development Officer













ANIX Stock - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings
or view top-rated stocks.

What is Anixa Biosciences' stock price forecast for 2023?

2 equities research analysts have issued 12 month price objectives for Anixa Biosciences' stock. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for ANIX
or view top-rated stocks among Wall Street analysts.

How have ANIX shares performed in 2023?

Anixa Biosciences' stock was trading at $4.25 at the start of the year. Since then, ANIX stock has decreased by 24.2% and is now trading at $3.22.
View the best growth stocks for 2023 here
.

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 9th 2023.
View our ANIX earnings forecast
.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) released its earnings results on Thursday, March, 16th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.08.

What other stocks do shareholders of Anixa Biosciences own?
What is Anixa Biosciences' stock symbol?

Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (2.07%), BlackRock Inc. (0.80%), Susquehanna International Group LLP (0.50%), Jane Street Group LLC (0.20%), Stifel Financial Corp (0.16%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends
.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anixa Biosciences' stock price today?

One share of ANIX stock can currently be purchased for approximately $3.22.

How much money does Anixa Biosciences make?

Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $99.56 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How can I contact Anixa Biosciences?

Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974.

This page (NASDAQ:ANIX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -